In patients with hepatocellular carcinoma, NPC2 downregulation is associated with adverse clinicopathological features by regulating mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) activation 31. This evidence concerns the gene NPC2 and hepatocellular carcinoma.